Vincerx Pharma Announces Compelling Clinical Efficacy of Enitociclib in Combination with Venetoclax and Prednisone in Lymphoma [Yahoo! Finance]
Vincerx Pharma, Inc. (VINC)
Company Research
Source: Yahoo! Finance
in 2 double-hit diffuse large b-cell lymphoma (DH-DLBCL) patients in ongoing dose-escalation trial of enitociclib in combination with venetoclax and prednisone Vincerx remains on target to report early clinical data from lead VersAptx™ platform compounds, VIP236 (early 2024) and VIP943 (mid 2024) PALO ALTO, Calif., Jan. 07, 2024 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC) (“Vincerx”), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today announced promising clinical results from a Phase 1 NIH-sponsored study of enitociclib in combination with venetoclax and prednisone for the treatment of relapsed/refractory lymphoma. “Enitociclib continues to differentiate itself in the CDK9 inhibitor field,” said Ahmed Hamdy, M.D., Chief Executive Officer of Vincerx. “Enitociclib is well tolerated, making it ‘the partner of choice' for novel combinations. We are pleased to see the high response
Show less
Read more
Impact Snapshot
Event Time:
VINC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VINC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VINC alerts
High impacting Vincerx Pharma, Inc. news events
Weekly update
A roundup of the hottest topics
VINC
News
- Vincerx Pharma Announces Pricing of Underwritten Public Offering of Common Stock and WarrantsGlobeNewswire
- Vincerx Pharma Announces Proposed Underwritten Public Offering of Common Stock and WarrantsGlobeNewswire
- Vincerx Pharma, Inc. (NASDAQ: VINC) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.MarketBeat
- Vincerx Pharma Presents Positive Preliminary Phase 1 Data for VIP236 and Updates on Pipeline Progress at the American Association for Cancer Research (AACR) Annual Meeting 2024 [Yahoo! Finance]Yahoo! Finance
- Vincerx Pharma Presents Positive Preliminary Phase 1 Data for VIP236 and Updates on Pipeline Progress at the American Association for Cancer Research (AACR) Annual Meeting 2024 GlobeNewswire
VINC
Sec Filings
- 4/26/24 - Form 8-K
- 4/25/24 - Form 8-K
- 4/25/24 - Form 424B5
- VINC's page on the SEC website